SCHEMBL3567710

SCHEMBL3567710

Cn1c(=O)ccc2c3cc(C(=O)NNC(=O)O)ccc3n(C)c21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.42
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ NLRP3 Q96P20 1/20 0.39
▸ MAPT P10636 8/20 0.39
▸ GAA P10253 4/20 0.39
▸ ALDH1A1 P00352 3/20 0.37
▸ HPGD P15428 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ ALOX15 P16050 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ SCN2B O60939 1/20 0.36
▸ SCN1A P35498 1/20 0.36
▸ SCN1B Q07699 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4765446 0.79 KDM4E (0.42) KDM4EMEN1KMT2ANLRP3MAPT
SCHEMBL3567581 0.75 KMT2A (0.40) KDM4EMEN1KMT2ANLRP3MAPT
SCHEMBL69291 0.65 KDM4E (0.83) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL3571739 0.65 KDM4E (0.43) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL22134574 0.64 SMN1; SMN2 (0.44) KDM4EMEN1KMT2ANLRP3MAPT
SCHEMBL2611198 0.62 NAMPT (0.44) KDM4EMEN1KMT2AMAPTALDH1A1
SCHEMBL28121877 0.62 KDM4E (0.61) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL3569292 0.61 KDM4E (0.58) KDM4EKMT2AALDH1A1HPGDHSD17B10
SCHEMBL13808817 0.61 MAPT (0.62) KDM4EMEN1KMT2AMAPTGAA
SCHEMBL21775981 0.61 KDM4E (0.64) KDM4EKMT2AMAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812165-B2 6-substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-10-12 — — US disclosed
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof PNPO, CYP2D6, DPYD KDM4E 3074/4885MEN1 1188/4885KMT2A 3979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback